High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?-Reference-Cited by-同舟云学术

High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?

Published:2020-12-15 Issue:5 Volume:182 Page:461-462
ISSN:1018-2438
Container-title:International Archives of Allergy and Immunology
language:en
Short-container-title:Int Arch Allergy Immunol

Author:

Türk Murat,Yılmaz İnsu

Publisher

S. Karger AG

Subject

Immunology,General Medicine,Immunology and Allergy

Reference4 articles.

1. Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321–32.

2. Gasser P, Tarchevskaya SS, Guntern P, Brigger D, Ruppli R, Zbären N, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.

3. Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–24.

4. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–414.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilizing Biologics in Drug Desensitization;Current Allergy and Asthma Reports;2022-11-29

2. Using National Registries to Identify Targeted Therapies for Refractory Urticaria;International Archives of Allergy and Immunology;2021